Please assess the completion status of the following clinical trial:

Trial Title: A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects at least 18 years of age.~2. Ability to understand and the willingness to sign a written informed consent.~3. Laboratory-confirmed SARS-CoV-2 infection as determined by a positive PCR test documented prior to randomization~4. Requirement for intensive inpatient hospital care~5. Acute hypoxemic respiratory failure typifying ARDS~6. Adequate liver function~7. Use of effective contraception~Exclusion Criteria:~1. Expected survival for less than 48 hours after randomization~2. Child-Pugh stage C hepatic impairment and/or portal hypertension secondary to cirrhosis~3. Stage IV chronic kidney disease or end-stage kidney disease on maintenance hemodialysis~4. Requirement for extra-corporeal membrane oxygenation (ECMO)~5. Acute Myocardial Infarction (AMI)~6. Active bleeding requiring transfusion~7. Concurrent participation in another clinical trial of experimental treatment for SARSCoV-2~8. Female patients who are pregnant or breastfeeding~9. Requirement for concurrent treatment with nitrates

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active GC4419 (Type: EXPERIMENTAL): Arm A
- Placebo (Type: PLACEBO_COMPARATOR): Arm B

Based on this trial design, predict the completion outcome and termination type (if applicable).